Association of Hepatitis B Virus Polymerase/Surface Gene Overlap Mutations Developed in Nucleos(t)id Analogue Treatments of Chronic Hepatitis B with Hepatocellular Carcinoma

Seda Erem Basmaz; Sadettin Hülagü; Murat Sayan

Makale detayları

Association of Hepatitis B Virus Polymerase/Surface Gene Overlap Mutations Developed in Nucleos(t)id Analogue Treatments of Chronic Hepatitis B with Hepatocellular Carcinoma

Yazarlar:

Seda Erem Basmaz | Sadettin Hülagü | Murat Sayan

Yayıncı:

Duzce University

Ana Başlıklar:

Gastroenterology and Hepatology

Dergi:

Duzce Medical Journal Vol.27 Issue 1, pp.58-63

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001338375

pISSN:

1307-671X

Anahtar kelimeler:

Özet:

 Aim: Nucleostid analogs NA used in hepatitis B virus HBV treatment may cause rtA181T and sW172 mutations. sW172 increases progression to hepatocellular carcinoma HCC. This study aimed to reveal the rtA181TsW172 mutation in HCC patients on the background of chronic hepatitis B CHB to determine its association with NA. Material and Methods: A total of 90 CHB patients, 42 patients with HCC DNA of 4 patients could not be analyzed, and 48 patients without HCC as the control group, were included in this study. Patients in the control group were divided into two groups, those who received NA treatment n21 and those who did not n21. Drug resistance analysis was performed by DNA sequencing. Results: Among the 42 patients with HCC, the median age was 63 range, 37-81 years, and the median HBV DNA level was 6.0x106 range, 30-1.14x108 IUml. In the 48 patients included as controls, the median age and HBV DNA level were 46 range, 20-75 years and 1.41x107 range, 80-1.70x108 IUml in the treatment-naive patients, and 36 range, 21-50 years and 7.6x106 range, 15.9x102 - 5.1x107 IUml in the NA-treated patients, respectively. sW172 mutation, which causes rtA181T mutation to occur, was identified in only 2 5.3 patients in the study group with HCC. Conclusion: Association between HCC and rtA181TsW172 mutation suggests that HCC may develop in patients under NA treatment. The rtA181TsW172 mutation should be screened in patients receiving treatment, and when detected, they should be closely monitored for HCC development.

 Aim: Nucleostid analogs NA used in hepatitis B virus HBV treatment may cause rtA181T and sW172 mutations. sW172 increases progression to hepatocellular carcinoma HCC. This study aimed to reveal the rtA181TsW172 mutation in HCC patients on the background of chronic hepatitis B CHB to determine its association with NA. Material and Methods: A total of 90 CHB patients, 42 patients with HCC DNA of 4 patients could not be analyzed, and 48 patients without HCC as the control group, were included in this study. Patients in the control group were divided into two groups, those who received NA treatment n21 and those who did not n21. Drug resistance analysis was performed by DNA sequencing. Results: Among the 42 patients with HCC, the median age was 63 range, 37-81 years, and the median HBV DNA level was 6.0x106 range, 30-1.14x108 IUml. In the 48 patients included as controls, the median age and HBV DNA level were 46 range, 20-75 years and 1.41x107 range, 80-1.70x108 IUml in the treatment-naive patients, and 36 range, 21-50 years and 7.6x106 range, 15.9x102 - 5.1x107 IUml in the NA-treated patients, respectively. sW172 mutation, which causes rtA181T mutation to occur, was identified in only 2 5.3 patients in the study group with HCC. Conclusion: Association between HCC and rtA181TsW172 mutation suggests that HCC may develop in patients under NA treatment. The rtA181TsW172 mutation should be screened in patients receiving treatment, and when detected, they should be closely monitored for HCC development.

 Aim: Nucleostid analogs NA used in hepatitis B virus HBV treatment may cause rtA181T and sW172 mutations. sW172 increases progression to hepatocellular carcinoma HCC. This study aimed to reveal the rtA181TsW172 mutation in HCC patients on the background of chronic hepatitis B CHB to determine its association with NA. Material and Methods: A total of 90 CHB patients, 42 patients with HCC DNA of 4 patients could not be analyzed, and 48 patients without HCC as the control group, were included in this study. Patients in the control group were divided into two groups, those who received NA treatment n21 and those who did not n21. Drug resistance analysis was performed by DNA sequencing. Results: Among the 42 patients with HCC, the median age was 63 range, 37-81 years, and the median HBV DNA level was 6.0x106 range, 30-1.14x108 IUml. In the 48 patients included as controls, the median age and HBV DNA level were 46 range, 20-75 years and 1.41x107 range, 80-1.70x108 IUml in the treatment-naive patients, and 36 range, 21-50 years and 7.6x106 range, 15.9x102 - 5.1x107 IUml in the NA-treated patients, respectively. sW172 mutation, which causes rtA181T mutation to occur, was identified in only 2 5.3 patients in the study group with HCC. Conclusion: Association between HCC and rtA181TsW172 mutation suggests that HCC may develop in patients under NA treatment. The rtA181TsW172 mutation should be screened in patients receiving treatment, and when detected, they should be closely monitored for HCC development.

 Amaç: Hepatit B virüsü HBV tedavisinde kullanılan nükleoztid analogları NA, rtA181T ve sW172 mutasyonlarına neden olabilir. sW172 hepatosellüler karsinoma hepatocellular carcinoma, HCC ilerlemesini artırır. Bu çalışmanın amacı, kronik hepatit B chronic hepatitis B, CHB zemininde HCC hastalarında rtA181TsW172 mutasyonunu ortaya koyarak NA kullanımı ile ilişkisini belirlemektir. Gereç ve Yöntemler: Bu çalışmaya, 42 HCCli hasta 4 hastanın DNAsı analiz edilemedi ve kontrol grubu olarak 48 HCCsiz hasta olmak üzere toplam 90 CHB hastası dahil edildi. Kontrol grubundaki hastalar, NA tedavisi alanlar n21 ve almayanlar n27 olmak üzere iki gruba ayrıldı. İlaç direnci analizi DNA sekanslama yöntemi ile gerçekleştirildi. Bulgular: HCCli 42 hastada, ortanca yaş 63 aralık, 37-81 yıl ve ortanca HBV DNA düzeyi 6,0x106 aralık, 30-1,14x108 IUml idi. Çalışmaya kontrol olarak dahil edilen 48 hastada, ortanca yaş ve HBV DNA düzeyi, sırasıyla, tedavi naif hastalarda 46 aralık, 20-75 yıl ve 1,41x107 aralık, 80-1,70x108 IUml ve NA tedavisi alan hastalarda 36 aralık, 21-50 yıl ve 7,6x106 aralık, 15,9x102 - 5,1x107 IUml idi. Çalışma grubundaki HCCli hastaların sadece 2sinde 5,3, rtA181T mutasyonunun ortaya çıkmasına neden olan sW172 mutasyonu tespit edildi. Sonuç: HCC ile rtA181TsW172 arasındaki ilişki, NA tedavisi alan hastalarda HCC gelişebileceğini düşündürmektedir. Tedavi alan hastalarda rtA181TsW172 mutasyonu taranmalı ve tespit edildiğinde hastalar HCC gelişimi açısından yakın takip edilmelidir.

Makale detayları

Association of Hepatitis B Virus Polymerase/Surface Gene Overlap Mutations Developed in Nucleos(t)id Analogue Treatments of Chronic Hepatitis B with Hepatocellular Carcinoma

Yazarlar:

Seda Erem Basmaz | Sadettin Hülagü | Murat Sayan

Yayıncı:

Duzce University

Ana Başlıklar:

Gastroenterology and Hepatology

Dergi:

Duzce Medical Journal Vol.27 Issue 1, pp.58-63

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001338375

pISSN:

1307-671X

Hepatocellular carcinoma

hepatitis B virus

drug resistance

nucleos(t)id analogHepatosellüler karsinom

hepatit B virüsü

ilaç direnci

nükleoz(t)id analoğu

Sayı

Makale detayları

Yazarlar: Seda Erem Basmaz | Sadettin Hülagü | Murat Sayan

Yayıncı: Duzce University

Ana Başlıklar: Gastroenterology and Hepatology

Dergi: Duzce Medical Journal Vol.27 Issue 1, pp.58-63

Belge Tipi: Makale

Yayın Tarihi: 4/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001338375

pISSN: 1307-671X

Sayı

Yazarlar:

Seda Erem Basmaz | Sadettin Hülagü | Murat Sayan

Yayıncı:

Duzce University

Ana Başlıklar:

Gastroenterology and Hepatology

Dergi:

Duzce Medical Journal Vol.27 Issue 1, pp.58-63

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001338375

pISSN:

1307-671X